CN Mobile Logo



Immunotherapy Combination Active in Advanced Melanoma

Treatment with nivolumab and ipilimumab in patients with advanced melanoma produced significantly higher rates of response and progression-free survival compared with ipilimumab alone.


Frequent consumers of citrus fruits were found to have an elevated risk of malignant melanoma.

New data suggests that cutaneous melanomas can be classified into four subtypes based on the pattern of the most prevalent significantly mutated genes.

A study of men taking PDE5 inhibitors found a small but significant increase in the incidence of malignant melanoma, though the association may not be causal.

As part of our 2015 ASCO Annual Meeting coverage, we discussed immunotherapy combinations in advanced melanoma patients with Michael A. Postow, MD.

Updated results from the coBRIM trial show that a BRAF/MEK inhibitor combination continues to provide clinical benefit in BRAF-positive metastatic melanoma.

Data from the KEYNOTE-001 study showed that the anti–PD-1 antibody pembrolizumab produces durable responses in metastatic melanoma patients.

Due to the genetic heterogeneity observed in tumors of melanoma patients who developed resistance to BRAF inhibitors, assessing mechanisms of resistance has minimal potential to inform further treatment decisions.


Subscribe to Melanoma on [sitename]
  • When you inspect moles, pay special attention to their sizes, shapes, edges, and color. A handy way to remember these features is to think of the A, B, C, D, and E of skin cancer—asymmetry, border, color, diameter, and evolving.

By clicking Accept, you agree to become a member of the UBM Medica Community.